Wham! Alexion investors sucker-punched as PTO takes up Amgen's Soliris patent challenge

Soliris
Blockbuster Soliris generated 88% of Alexion Pharmaceuticals' sales last year. (Alexion)

Alexion Pharmaceuticals investors were celebrating last week when word on the street said Amgen might buy out the company, but a week later, their mood is much different.

The buyout hope was dashed Monday when Amgen announced it would buy Celgene’s Otezla, and now the U.S. Patent and Trademark Office (PTO) has struck up a review of key Soliris patents—thanks to a challenge from none other than Amgen. 

The PTO’s Patent Trial and Appeal Board (PTAB) will review numerous claims contained in three Soliris patents, according to documents posted on the agency’s website Friday. Soliris accounted for 88% of the biotech's sales last year.

Webinar

De-risking the Development of Biotherapeutics Using Early Stage In Vitro Expression and Genetic Characterisation Tools

Wednesday, July 8, 2020 | 11am EST / 8am PST

This webinar will describe strategies to mitigate risks, reduce attrition and help improve the quality and safety of your drug candidate.

Just Thursday evening, SVB Leerink analyst Geoffrey Porges echoed the general analyst sentiment in calling a PTAB review “unlikely.” Alexion investors sent shares down about 7.5% when the market opened Friday. 

Amgen alleged in a February petition that the “patented subject matter was anticipated and/or obvious in view of prior art, and that the patent claims are therefore invalid,” Alexion disclosed in a July quarterly filing (PDF). 

Before PTAB instituted the reviews, Porges said he expected Alexion to prevail in the case. His team has projected no U.S. biosimilars to Soliris until 2027. Still, even if Amgen wins the case, its biosimilar wouldn't be ready to launch until 2022 at the earliest given its current development status, the analyst wrote.  

PTAB reviews typically take one year, and Porges figures Alexion's "stock is likely to exist in a depressed state" until then.

RELATED: Alexion runs toward big Ultomiris goals with early Soliris switching success 

Soliris generated $1.24 billion in the U.S. last year and $3.14 billion globally, representing 88% of Alexion’s overall sales. The company has "multiple lines of defense" against Amgen or other biosim makers, Porges wrote, but Friday's news could render some of them "less viable."

Meanwhile, Alexion late last year won approval for Soliris follow-up Ultomiris. It's working to switch patients to the newer med and drive uptake for that drug, and so far those efforts are pacing ahead.

Suggested Articles

Johnson & Johnson has expanded its COVID-19 vaccine production pact with CDMO Catalent to include work at the manufacturer's Anagni, Italy site.

German vaccine maker CureVac scored an $85 million EU loan to expand manufacturing for its mRNA-based COVID-19 vaccine hopeful.

Learn how drug substance and drug product early development strategies are important for optimization and long-term success.